Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2013 by GlaxoSmithKline
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00968968
First received: August 27, 2009
Last updated: October 4, 2013
Last verified: September 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: August 2014
  Estimated Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)